Overall rank by patents
#45,540
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).
The verdict
According to USPTO PatentsView, Celonova ranks #45,540 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.
USPTO PatentsView assignee plate
Corpus R45540 · US Corporation #45,540 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Cell Therapy AND Technology S.A. DE C.V. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Celonova Stent · this assignee
24 score
3D Lighting… · lowest
7 score
What this shows Celonova's Innovation Score is 24.3/100 (14th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Celonova Stent, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Celonova sits between Cell Therapy AND Technology S.A. DE C.V. and Centenary Institute OF Cancer Medicine AND Cell Biology.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Cell Therapy AND Technology S.A. DE C.V.
5 patents
Cellact Pharma GMBH
5 patents
Cellblock FCS, LLC
5 patents
Cellomat Israel Ltd.
5 patents
Celsia Technologies Taiwan, Inc.
5 patents
CENDRES+METAUX SA
5 patents
Censhare GMBH
5 patents
Centenary Institute OF Cancer Medicine AND Cell Biology
5 patents
Celonova Stent, Inc.
5 patents
What this shows Celonova holds 5 patents at rank #45,474, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #45,474 in granted patent volume.
Other assignees with the most granted patents in Celonova's primary technology class.
Celonova's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
24 14th percentile higher than 14% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 20.0% |
| 2016 | 2 | 40.0% |
| 2019 | 2 | 40.0% |
Top 4 of 4 technology areas
Overall rank by patents
#45,540
of 49,997 tracked assignees
24.3 out of 100
What to do with this data
Celonova Stent, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.